Could a DNA-Repair blocker slow recurrent brain tumors?
NCT ID NCT03561870
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This study tested the drug olaparib in 35 adults with a specific type of aggressive brain tumor (IDH-mutant high-grade glioma) that had returned after standard treatments. The drug works by taking advantage of a weakness in the tumor cells' ability to repair their DNA. The main goal was to see if olaparib could keep the cancer from growing for at least 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT IDH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospices Civils de Lyon
Bron, France
Conditions
Explore the condition pages connected to this study.